Toxicity and efficacy of antibody–drug conjugates in advanced solid tumors: a retrospective single-center analysis of clinical trials
ADCs show activity across tumor types, with greater efficacy when targeting oncogenes. Toxicities are frequent and often early. Anticipating timing of toxicities is key to effective clinical management.
Authors
- Elisa Fontana (ORCID: https://orcid.org/0000-0002-4991-9355)
- Aldo Cammarota (ORCID: https://orcid.org/0000-0003-4211-5140)
- Rafael Grochot (ORCID: https://orcid.org/0000-0002-2156-9197)
- R. Woodford
- Charles Swanton (ORCID: https://orcid.org/0000-0002-4299-3018)
- Andrew Williams (ORCID: https://orcid.org/0000-0002-7637-7686)
- Kroopa Joshi
- N. Beygozlu
- H Almarzouq
Institutions
- The Francis Crick Institute (GB)
- University College London (GB)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1016/j.esmoop.2025.105573
- Citations
- 1
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 1.05